Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Current Deferred Revenue: 2015-2024

Historic Current Deferred Revenue for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to $60.4 million.

  • Editas Medicine's Current Deferred Revenue fell 21.32% to $54.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.2 million, marking a year-over-year decrease of 21.32%. This contributed to the annual value of $60.4 million for FY2024, which is 12.29% down from last year.
  • Per Editas Medicine's latest filing, its Current Deferred Revenue stood at $60.4 million for FY2024, which was down 12.29% from $68.9 million recorded in FY2023.
  • Editas Medicine's 5-year Current Deferred Revenue high stood at $94.9 million for FY2020, and its period low was $60.4 million during FY2024.
  • Its 3-year average for Current Deferred Revenue is $66.1 million, with a median of $68.9 million in 2023.
  • Data for Editas Medicine's Current Deferred Revenue shows a maximum YoY crashed of 49.16% (in 2020) over the last 5 years.
  • Over the past 5 years, Editas Medicine's Current Deferred Revenue (Yearly) stood at $94.9 million in 2020, then decreased by 23.92% to $72.2 million in 2021, then fell by 4.62% to $68.9 million in 2022, then remained steady at $68.9 million in 2023, then dropped by 12.29% to $60.4 million in 2024.